Doctors and scientists have been working for years to find a cancer cure that can effectively treat the patients. Since the cancerous tumors have been found to have more than just one kind of cancer cell, this could explain why there are many types that make the disease hard to treat.
This may also be the reason why a certain type of cure or medicine may work for some types of cancers but not for others. It was said that to solve this problem, cancer treatments that are being used today are usually a combination of therapies to hit the tumor and eradicate it from the body.
Cancer cells can change
As per the Roswell Park Comprehensive Cancer Center, cancer cure is taking a long time to arrive because most drugs work well in the initial tries but later, the cancerous cells become resistant to them so they continue to grow. This is because the tumors can mutate and these deadly cells have a high chance of doing this mutation that makes them resist the drugs.
The only thing that patients can do when the drug turned resistant is to shift to another treatment. “Yes, patients have to change therapies, and they’re on therapies for a long time, but their lives can be extended for years and years,” the center’s Dr. Joyce Ohm stated.
The cancerous cells can live for a long time
Cancer cells can survive and live for a long time and with their capacity to “stay alive,” the treatments and medicines may not work for as long as expected. Also, it was added that these cells can always find ways to protect themselves from medicines or treatments. As a result, these treatments become useless and doctors need to formulate new ones.
The working treatment right now is the immunotherapy but as times go by, its effect is also becoming weaker perhaps, because the cancer cells are mutating or have found methods to evade it. Will a cancer cure ever be found? Doctors stated that they are doing their best and somehow making some progress.
“We’re making progress,” Dr. Ohm said. “It feels slow, and sometimes it’s not fast enough for our patients. We know that, and that’s hard, but we are making tremendous progress. Today, when treatments do fail, we have a bigger toolbox.”


GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak
Trump Signs Order to Cut Routine Childhood Vaccines
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
U.S. Issues Cuba Health Alert as Illnesses Rise
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 



